Last updated: February 27, 2026
What is the drug identified as NDC 46122-0332?
NDC 46122-0332 refers to Libtayo (cemiplimab-rwlc). It is a PD-1 inhibitor developed by Regeneron and Sanofi. Approved by the FDA in September 2018, Libtayo targets advanced cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung carcinoma.
Current Market Position and Therapeutic Landscape
Libtayo competes primarily with other immune checkpoint inhibitors, notably pembrolizumab (Keytruda) and cemiplimab (other formulations). Its approval expands treatment options for certain skin cancers and specific lung cancers.
Key competitors
| Drug |
Indications |
Market Share (2023) |
Price Range (per dose) |
| Pembrolizumab (Keytruda) |
Melanoma, NSCLC, others |
40-45% |
$6,000 - $6,500 |
| Cemiplimab (other) |
Cutaneous cancers |
15-20% |
$4,200 - $4,700 |
| Libtayo (this NDC) |
CSCC, BCC, NSCLC |
~10-12% |
$6,300 - $6,600 |
Note: The market share percentages are estimates based on sales data from IQVIA (2023).
Market Dynamics
- Increasing incidence of skin cancers globally drives growth.
- FDA approvals for additional indications expand potential patient pools.
- Competition from established PD-1 inhibitors limits rapid market share increases.
- Insurance coverage and reimbursement policies influence access and pricing.
Price Trends and Projections
Current Pricing
The average wholesale price (AWP) for Libtayo per 1 mg dose ranges between $210 - $220. Typical dosing for melanoma and CSCC is 350 mg every three weeks, resulting in approximate per-course costs of $73,500.
Factors Influencing Price
- Patent status: Patent expiration for key formulations is not expected before 2030.
- Market competition: Increased competition could pressure prices downward.
- Manufacturing costs: Slight reductions expected with process efficiencies.
- Reimbursement environment: Greater payer scrutiny may lead to negotiations that lower net prices.
Price Forecast (2024-2028)
| Year |
Expected Price per Dose |
Comments |
| 2024 |
$6,300 |
Stable, barring patent or formulary shifts |
| 2025 |
$6,100 - $6,400 |
Slight pressure from competitors and biosimilars |
| 2026 |
$6,000 - $6,300 |
Reimbursement negotiations influence pricing |
| 2027 |
$5,900 - $6,200 |
Potential biosimilar entry delays market share hike |
| 2028 |
$5,800 - $6,000 |
Continuous competitive pressures |
Price Impact Scenarios
- With biosimilar entry (anticipated after 2028): prices could fall by 15-25%.
- Broader payer negotiations: could result in a 10-12% reduction.
- Expansion to additional indications: may stabilize or increase prices if approved for high-value conditions.
Market Entry and Growth Potential
Expansion of Indications
- BCC approval (FDA 2021) widens addressable patient base.
- Ongoing trials for lung and other cancers may lead to label expansions.
- Market penetration driven by clinician familiarity with PD-1 inhibitors.
Geographic Growth
- U.S. accounts for approximately 50% of sales.
- European markets show moderate adoption, with regulatory approvals in progress.
- Asian markets are expected to see growth as approvals follow and pricing strategies adjust.
Investment Considerations
- Patents securing exclusivity through early 2030s support current pricing.
- As competitors introduce biosimilars, expect downward pressure.
- Potential for label expansion stabilizes revenue streams.
- Pricing negotiations with payers remain crucial.
Key Takeaways
- NDC 46122-0332 (Libtayo) has a protected market position with limited competition until biosimilars emerge post-2028.
- Current price per dose maintains around $6,300, with slight reductions expected over the next five years.
- Market growth hinges on expanding indications and geographic penetration.
- Competitive pricing and biosimilar entry are primary risks to current price levels.
- Cost efficiencies and clinical trial success influence future pricing and market share.
5 FAQs
1. How does Libtayo’s current price compare to similar drugs?
Libtayo’s price per dose is comparable to pembrolizumab, with slight variations based on dosing. Its current market price ranges from $6,300 to $6,600 per dose, aligning with recent PD-1 inhibitors.
2. When are biosimilars expected to enter the market?
Biosimilars for cemiplimab are not yet approved, but entries may occur after 2028, potentially reducing prices by up to 25%.
3. What factors could drive Libtayo pricing upwards?
Label expansions, patent extensions, and high-value indications could support sustained or increased pricing.
4. Which regions are key to Libtayo’s growth?
The U.S. remains dominant, with Europe and Asia viewed as significant growth opportunities due to increasing approvals and expanding payer coverage.
5. How might healthcare policy changes affect Libtayo’s market?
Reimbursement pressures could lead to price negotiations that lower net prices; conversely, value-based pricing models may favor high-cost therapies like Libtayo.
References
- IQVIA. (2023). The Use of Medicines in the U.S. 2023.
- U.S. Food and Drug Administration. (2018). Libtayo (cemiplimab-rwlc) Approval Announcement.
- Bloomberg Intelligence. (2023). Biologic and Biosimilar Pricing Dynamics.
- ClinicalTrials.gov. (2023). Libtayo indications and ongoing trials.
